Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares dropped 2.7% on Wednesday after UBS Group lowered their price target on the stock from $28.00 to $24.00. UBS Group currently has a neutral rating ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Value investors rely on traditional forms of analysis on ... watch right now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with ...